Navigation Links
Curemark Begins Autism Trials at Two More Sites
Date:6/1/2010

RYE, N.Y., June 1 /PRNewswire/ -- Curemark, LLC, (www.curemark.com), a drug research and development company focused on the treatment of neurological diseases, announced that the company has opened clinical trial enrollment for CM-AT, its autism treatment, at the University of Pittsburgh and the Alexian Brothers Behavioral Health Hospital in Hoffman Estates, Illinois, near Chicago.  A total of 12 sites nationwide are recruiting patients for CM-AT Phase III clinical trials.

CM-AT is based on Curemark's research that showed enzyme deficiencies in autistic children, resulting in an inability to digest protein.  The inability to digest protein affects the production of amino acids, the building blocks of chemicals essential for brain function.  CM-AT has received Fast Track status from the FDA.  If approved, it will be one of the first therapies to address the underlying physiology of autism.

"Curemark's clinical trial program is making rapid progress, with enrollment moving forward quickly at our CM-AT trial sites," said Dr. Joan Fallon, Curemark founder and CEO.  "We're also considering additional sites with potential interest in participating in the CM-AT clinical research."  

For information on enrolling in the Curemark CM-AT autism trials, log on to www.clinicaltrials.gov and search "Curemark."

About CUREMARK LLC

Curemark is a drug research and development company focused on the treatment of neurological and other diseases, especially those with dysautonomic components, by addressing certain key gastrointestinal/pancreatic secretory deficiencies. The company's initial products are based upon breakthrough observations by its founder, Dr. Joan Fallon, which revealed a lack of protein digestion in children with autism and ADHD. To learn more about our innovative science, visit www.curemark.com

Safe Harbor Statement

This news release contains forward-looking statements that involve risks and uncertainties that could cause our actual results and experiences to differ materially from anticipated results and expectations expressed in such forward-looking statement. These forward-looking statements include, without limitation, statements regarding the mechanism of action of CM-AT, its potential advantages, its potential for use in treating autism, as well as the timing, progress and anticipated results of the clinical development and regulatory processes concerning CM-AT. These statements are based on our current beliefs and expectations as to such future outcomes, and are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. Factors that might cause such a material difference include, among others, risks that the results of clinical trials will not support our claims or beliefs concerning the effectiveness of CM-AT, our ability to finance our development of CM-AT, regulatory risks, and our reliance on third party researchers and other collaborators. We assume no obligation to update these statements, except as required by law.


'/>"/>
SOURCE Curemark, LLC
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Dr. Joan Fallon, Curemark CEO, Addresses Keystone Symposia Meeting On Autism
2. Curemark Adds UC Davis MIND Institute to Autism Clinical Trial Sites
3. Curemark CM-AT Autism Treatment Granted FDA Fast Track Status
4. Curemark Enrolling Patients In Phase III Autism Trials At Ten Sites
5. Curemark Opens Patient Enrollment for Autism Treatment at Three More Clinical Trial Sites
6. Curemark Enrolls First Patients in Phase III Clinical Trials for Autism Treatment
7. Curemark Announces Senior Executive Promotions
8. Curemark CEO Presents at Epigenomics Conference
9. Curemark Closes Series A Financing
10. Curemark Appoints Preeminent Pediatrics Gastroenterologist
11. ThromboGenics and BioInvent to Receive EUR10 Million Milestone as Partner Roche Begins New Clinical Study with TB-403
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... BOGOTA, Colombia , June 23, 2016  Astellas today announced the establishment of Astellas Farma Colombia ... the company,s second affiliate in Latin America . ... ... Farma Colombia ... ...
(Date:6/23/2016)... -- Guerbet announced today that it has been named a ... One of 12 suppliers to receive the ... of Premier members through exceptional local customer service and ... lower costs. "We ... customer service from Premier," says Massimo Carrara , ...
(Date:6/23/2016)... June 23, 2016 Research and ... Procedure Volumes: Global Analysis (United States, China, Japan, Brazil, ... report to their offering. ... for healthcare business planners, provides surgical procedure volume data ... trends with an in-depth analysis of growth drivers and ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary Hypertension Association (PHA) ... will receive two significant new grants to support its work to advance research ... anniversary by recognizing patients, medical professionals and scientists for their work in fighting ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience with all areas ... , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct ...
(Date:6/24/2016)... ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain ... for a minimum wage raise to $12 an hour by 2020 and then adjusting it ... the lost value of the minimum wage, assure the wage floor does not erode again, ...
(Date:6/24/2016)... ... June 24, 2016 , ... EB ... Decision Making in Emergency Medicine conference in Ponte Vedra Beach, FL. The awards ... in Emergency Medicine Practice and Pediatric Emergency Medicine Practice. , “With ...
(Date:6/24/2016)... ... June 24, 2016 , ... Puradigm® & Innovative Solutions ... initiated cultivation and processing operations at its production facility, and opened its first ... is the manufacturer of a complete system of proactive air and surface purification ...
Breaking Medicine News(10 mins):